Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Zogenix, Inc. (NASDAQ:ZGNX) — a biopharma company,developing treatments for patients with rare central nervous system conditions with limited or no treatment options — could be in for further upside. This is on top of the triple-digit gains posted in late September following the release of positive trial results for its Dravet Syndrome, or DS, treatment candidate ZX007, in a late-stage study.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
JMP Securities analyst Jason Butler initiated coverage of the company with a Market Outperform rating and $56 price target.
The Thesis
Confidence in the results could continue to strengthen, with the presentation of the results at the American Epilepsy Society meeting in December, Butler said in a note. (See Butler's track record here.)
The results from Zogenix' second Phase 3 trial are expected to be released in the second quarter of 2018, Butler said. An NDA submission is likely in the second half of 2018, the analyst said.
Butler estimates U.S. peak sales potential of about $750 million in DS, suggesting upside to the company's enterprise value of about $1.2 billion.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The analyst said further upside exists from the development of ZX008 in other seizure disorders, mainly Lennox-Gastaut syndrome. A Phase 3 trial for this indication is set to begin by the end of 2017, Butler said.
"We believe the potential for Z008 in seizure disorders beyond DS is currently underappreciated in the stock."
The Price Action
At the time of writing, Zogenix shares were down 1.80 percent at $38.10. The shares are up a whopping 215 percent year-to-date.
Related Links:
Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon
Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.